SVB Securities analyst David Risinger maintained a Hold rating on Regeneron (REGN – Research Report) on December 14. The company’s shares closed yesterday at $731.27. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Roivant Sciences. According to TipRanks, Risinger has an average return of 5.1% and a 57.44% success rate on recommended stocks.  Currently, the analyst consensus on Regeneron is a Moderate Buy with an average price target of $831.21. See today’s best-performing stocks on TipRanks >> REGN market cap is currently $81.66B and has a P/E ratio of 15.81.
		  Based on the recent corporate insider activity of 95 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of REGN in relation to earlier this year. Last month, McCourt Marion, the EVP Commercial of REGN sold 1,000.00 shares for a total of $727,820.00. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.  Read More on REGN: Indices Commodities Currencies Stocks